FDA Approves Vectibix ® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer
Vectibix Demonstrated an Improvement in Overall Survival in Patients With Wild-Type RAS Metastatic Colorectal Cancer
Predictive Biomarkers Allow Physicians to More Accurately Identify Treatments to Potentially Optimize Cancer Care
Approved Companion Diagnostic Tool Strengthens Precision Medicine Approach
THOUSAND OAKS, Calif., June 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Vectibix® (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal ca...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Food and Drug Administration (FDA) | Pharmaceuticals